| Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript |
Humacyte, Inc. (NASDAQ:HUMA ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Thomas Johnson - Director-Corporate Communications, LifeSci Advisors, IR Laura Niklason - Founder, President and Chief Executive Officer Dale Sander - Chief Financial Officer, Chief Corporate Development Officer and Treasurer BJ Scheessele - Chief Commercial Officer Conference Call Participants Ryan Zimmerman - BTIG Josh Jennings - TD Cowen Kristen Kluska - Cantor Fitzgerald Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen and welcome to the Humacyte's First Quarter Results Conference Call. Currently, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-13 18:29:05 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates |
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago. |
zacks.com |
2025-05-13 13:45:45 |
Czytaj oryginał (ang.) |
| Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update |
- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - |
globenewswire.com |
2025-05-13 11:30:00 |
Czytaj oryginał (ang.) |
| Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 |
DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on Tuesday, May 13, 2025. |
globenewswire.com |
2025-05-09 12:00:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know |
The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.45, representing a +1.4% change from its previous close. |
zacks.com |
2025-04-30 23:05:36 |
Czytaj oryginał (ang.) |
| All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy |
Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-04-30 17:00:46 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note |
Humacyte, Inc. (HUMA) reachead $1.48 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close. |
zacks.com |
2025-04-24 23:00:41 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know |
Humacyte, Inc. (HUMA) reachead $1.55 at the closing of the latest trading day, reflecting a +0.65% change compared to its last close. |
zacks.com |
2025-04-16 23:20:37 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript |
Humacyte, Inc. (NASDAQ:HUMA ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, IR Laura Niklason - President and CEO Dale Sander - CFO and Chief Corporate Development Officer Conference Call Participants Josh Jennings - TD Cowen & Company Ryan Zimmerman - BTIG Vernon Bernardino - H.C. Wainwright Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen. |
seekingalpha.com |
2025-03-28 15:48:49 |
Czytaj oryginał (ang.) |
| Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update |
- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - |
globenewswire.com |
2025-03-28 09:30:00 |
Czytaj oryginał (ang.) |
| Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet |
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. |
zacks.com |
2025-03-26 12:30:36 |
Czytaj oryginał (ang.) |
| Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025 |
DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31, 2024, on Friday, March 28, 2025. |
globenewswire.com |
2025-03-26 10:00:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. Announces Pricing of Public Offering of Common Stock |
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about March 27, 2025, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 3,750,000 shares of Humacyte's common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte. |
globenewswire.com |
2025-03-25 22:35:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. Announces Proposed Public Offering of Common Stock |
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering of its common stock. In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares are being offered by Humacyte. |
globenewswire.com |
2025-03-25 18:01:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. (HUMA) Flat As Market Gains: What You Should Know |
In the closing of the recent trading day, Humacyte, Inc. (HUMA) stood at $3.32, denoting no change from the preceding trading day. |
zacks.com |
2025-03-24 21:05:45 |
Czytaj oryginał (ang.) |
| Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics |
– Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – |
globenewswire.com |
2025-03-10 10:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy? |
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? |
zacks.com |
2025-03-07 12:30:49 |
Czytaj oryginał (ang.) |
| Trestle Bio Announces Research Collaboration with Humacyte |
SAN DIEGO--(BUSINESS WIRE)--Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale. Trestle Bio is a preclinical stage company developing bioengineered kidney tissues for patients suffering from end stage renal disease (ESRD). The collaboration will explore technology synergies for bioengineering vascularized or. |
businesswire.com |
2025-03-06 10:00:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade |
Humacyte, Inc. (HUMA) closed the most recent trading day at $3.15, moving -1.56% from the previous trading session. |
zacks.com |
2025-03-05 21:00:47 |
Czytaj oryginał (ang.) |
| Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 |
DURHAM, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced it will host an in-person and virtual investor event in New York on Thursday, March 6, 2025 at 12:00 PM ET. To register as an in-person or virtual attendee, please click here. |
globenewswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know |
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $3.37, indicating a -1.75% shift from the previous trading day. |
zacks.com |
2025-02-27 21:00:28 |
Czytaj oryginał (ang.) |
| Humacyte to Present at the TD Cowen 45th Annual Health Care Conference |
DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D. |
globenewswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues |
– Patent provides coverage into 2040 for key aspects of the bioreactor manufacturing system – – Symvess, the acellular tissue engineered vessel, is manufactured in this patented system – DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the issuance of a U.S. Patent covering key aspects of the manufacturing of Symvess (acellular tissue engineered vessel-tyod) and other bioengineered human tissues. |
globenewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma |
– The FDA has authorized Humacyte to release commercial shipments – – Positive responses from surgeons and trauma centers to initial sales and marketing outreach – - 21 hospitals have already initiated the Value Analysis Committee (VAC) approval process – DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the commercial launch of Symvess (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible. |
globenewswire.com |
2025-02-26 10:00:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA |
PHILADELPHIA, PA / ACCESS Newswire / February 20, 2025 / Kehoe Law Firm, P.C. is investigating whether certain officers and directors of Humacyte, Inc. ("Humacyte") (NASDAQ:HUMA) breached their fiduciary duties by failing to manage Humacyte in an acceptable manner and whether Humacyte and its shareholders were harmed as a result. |
accessnewswire.com |
2025-02-20 15:35:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights |
Humacyte, Inc. (HUMA) closed the most recent trading day at $3.96, moving -1.25% from the previous trading session. |
zacks.com |
2025-02-12 21:01:25 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why |
Humacyte, Inc. (HUMA) concluded the recent trading session at $4.37, signifying a +1.63% move from its prior day's close. |
zacks.com |
2025-02-04 21:20:43 |
Czytaj oryginał (ang.) |
| HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Humacyte, Inc. (NASDAQ: HUMA) on behalf of long-term stockholders following a class action complaint that was filed against Humacyte on November 18, 2024 with a Class Period from May 10, 2024 to October 17, 2024. Our investigation concerns whether the board of directors of Humacyte have breached their fiduciary duties to the company. |
globenewswire.com |
2025-01-23 23:00:00 |
Czytaj oryginał (ang.) |
| Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting |
– Plans for filing an IND was agreed with the FDA in a recent meeting – – Positive preclinical results of the small-diameter ATEV were recently presented at The American Heart Association's Scientific Sessions 2024 meeting – DURHAM, N.C., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that it plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to allow first-in-human clinical testing of the small-diameter (3.5mm) acellular tissue engineered vessel (sdATEV) in coronary artery bypass grafting (CABG). |
globenewswire.com |
2025-01-21 10:00:00 |
Czytaj oryginał (ang.) |
| January 17, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against HUMA |
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=123538&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-01-17 18:15:00 |
Czytaj oryginał (ang.) |
| HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm |
LOS ANGELES--(BUSINESS WIRE)--HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm. |
businesswire.com |
2025-01-17 14:28:00 |
Czytaj oryginał (ang.) |
| Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for Investors - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=123437&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-01-17 13:15:00 |
Czytaj oryginał (ang.) |
| HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA |
NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), of the important January 17, 2025 lead plaintiff deadline. |
globenewswire.com |
2025-01-17 12:47:00 |
Czytaj oryginał (ang.) |
| HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights |
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024. Humacyte describes itself as a company that “engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-36. |
businesswire.com |
2025-01-17 12:30:00 |
Czytaj oryginał (ang.) |
| Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA |
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options |
globenewswire.com |
2025-01-17 11:44:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA |
NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=123415&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-01-17 11:30:00 |
Czytaj oryginał (ang.) |
| DEADLINE TODAY: The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Humacyte, Inc. |
LOS ANGELES, CA / ACCESS Newswire / January 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025. |
accessnewswire.com |
2025-01-17 11:15:00 |
Czytaj oryginał (ang.) |
| FINAL REMINDER HUMA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Humacyte, Inc. Investors to Participate in the Class Action Lawsuit |
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024 inclusive (the "Class Period"). |
accessnewswire.com |
2025-01-17 09:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - HUMA |
NEW YORK , Jan. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Humacyte, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and October 17, 2024. |
prnewswire.com |
2025-01-17 07:45:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA |
LOS ANGELES , Jan. 17, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Humacyte, Inc. ("HUMA" or "the Company") (NASDAQ: HUMA) for violations of the federal securities laws. Shareholders who bought the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact DJS Law Group before January 17, 2025. |
prnewswire.com |
2025-01-17 07:14:00 |
Czytaj oryginał (ang.) |
| January 17, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against HUMA |
NEW YORK, NY / ACCESSWIRE / January 4, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120647&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-04 23:23:00 |
Czytaj oryginał (ang.) |
| Class Action Filed Against Humacyte, Inc. (HUMA) - January 17, 2025 Deadline to Join - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESSWIRE / January 4, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120630&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-04 20:01:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Humacyte Inc |
LOS ANGELES, CA / ACCESSWIRE / January 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025. |
accesswire.com |
2025-01-04 11:30:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120592&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-03 18:45:00 |
Czytaj oryginał (ang.) |
| HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit |
NEW YORK , Jan. 3, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline. So What: So what: If you purchased Humacyte securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
prnewswire.com |
2025-01-03 18:31:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120523&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-03 14:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Humacyte, Inc. of Class Action Lawsuit and Upcoming Deadlines - HUMA |
NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ:HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. |
accesswire.com |
2025-01-03 14:00:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - HUMA |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120477&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-03 12:00:00 |
Czytaj oryginał (ang.) |
| Humacyte Inc Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / January 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025. |
accesswire.com |
2025-01-03 11:30:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Humacyte, Inc. (HUMA) should contact Levi & Korsinsky about pending Class Action - HUMA |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120408&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-03 09:15:00 |
Czytaj oryginał (ang.) |
| HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024 inclusive (the "Class Period"). |
accesswire.com |
2025-01-03 09:00:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA |
NEW YORK , Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Humacyte, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and October 17, 2024. |
prnewswire.com |
2025-01-03 07:30:00 |
Czytaj oryginał (ang.) |
| Lost Money on Humacyte, Inc.(HUMA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120351&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-02 20:45:00 |
Czytaj oryginał (ang.) |
| ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA |
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), of the important January 17, 2025 lead plaintiff deadline. |
globenewswire.com |
2025-01-02 18:08:00 |
Czytaj oryginał (ang.) |
| Humacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit |
LOS ANGELES , Jan. 2, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). IF YOU SUFFERED A LOSS ON YOUR HUMACYTE INVESTMENTS, CLICK HERE BEFORE JANUARY 17, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About? |
prnewswire.com |
2025-01-02 18:06:00 |
Czytaj oryginał (ang.) |
| HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline |
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120211&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-02 15:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA |
NEW YORK, NY / ACCESSWIRE / January 1, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120011&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-02 14:30:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Humacyte Inc. |
LOS ANGELES, CA / ACCESSWIRE / January 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025. |
accesswire.com |
2025-01-02 14:15:00 |
Czytaj oryginał (ang.) |
| The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders |
NEW YORK , Jan. 2, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
prnewswire.com |
2025-01-02 13:40:00 |
Czytaj oryginał (ang.) |
| Contact Levi & Korsinsky by January 17, 2025 Deadline to Join Class Action Against Humacyte, Inc. (HUMA) |
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120155&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2025-01-02 12:30:00 |
Czytaj oryginał (ang.) |